MedTrace Logo

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 313

Last updated 2022-03-09

Study results available
· View outcomes & findings →

Summary

Phase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

Cabiralizumab

Solution for IV administration

BIOLOGICAL

Nivolumab

Solution for IV administration

Sponsors & Collaborators

Principal Investigators

  • Medical Lead · Five Prime Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-08
Primary Completion
2019-11-18
Completion
2019-11-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526017 on ClinicalTrials.gov